{"id":"NCT04714359","sponsor":"Lykos Therapeutics","briefTitle":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","officialTitle":"A Multi-Site Open-Label Safety Extension Study of Manualized MDMA-Assisted Psychotherapy for the Treatment of Participants With Posttraumatic Stress Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-08","primaryCompletion":"2023-11-01","completion":"2023-11-06","firstPosted":"2021-01-19","resultsPosted":"2024-11-29","lastUpdate":"2025-06-06"},"enrollment":87,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["PTSD"],"interventions":[{"type":"DRUG","name":"Midomafetamine HCl","otherNames":["3,4-methylenedioxymethamphetamine","MDMA HCl","midomafetamine","MDMA"]}],"arms":[{"label":"MDMA-assisted therapy","type":"EXPERIMENTAL"}],"summary":"The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing PTSD symptoms in people with PTSD who received placebo in a prior MDMA-assisted therapy study.\n\nThe main question it aims to answer is:\n\nDo PTSD symptoms decrease in people who receive a flexible dose of MDMA (120 or 180 mg MDMA HCl) with therapy in three sessions?\n\nParticipants will undergo three preparatory therapy sessions without any study drug, then three MDMA-assisted therapy sessions with a flexible dose of 80 or 120 mg, followed by three integrative therapy sessions without study drug after each MDMA-assisted therapy session.","primaryOutcome":{"measure":"Change From Baseline to Visit 16 in PCL-5 Total Score","timeFrame":"Baseline enrollment to approximately 18 weeks later (Visit 16 occurs 24 to 32 days after Experimental Session 3)","effectByArm":[{"arm":"MDMA-assisted Therapy","deltaMin":-14.92,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":9},"locations":{"siteCount":15,"countries":["United States","Canada","Israel"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":85},"commonTop":["Muscle tightness","Headache","Nausea","Decreased appetite","Suicidal ideation"]}}